EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC-ND 4.0

VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment

Jade Ghosn iD, Federico Pulido iD, Gustavo D Lopardo, Anita Olczak iD, Diego Ripamonti iD, Charlotte Martin iD, Orlando Paredes Ceballos, Hartmut Stocker, Maria Josefina Mendez Vazquez iD, Hiroyuki Gatanaga iD, Simeon Metallidis, Daniel Elbirt iD und 17 weitere

Open Forum Infectious Diseases · 01.08.2026 · 13 (8)

DOI: 10.1093/ofid/ofag471 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 28.07.2026. Verfasst von Jade Ghosn und 28 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR 1137 IAME, Université Paris Cité, Paris, France. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Antiretroviral therapy (ART) that achieves virologic suppression using fewer antiretroviral agents is an optimized approach to HIV-1 treatment initiation. VOGUE is the first randomized, head-to-head study comparing the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) with the 3-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as initial ART, including among individuals with high viral loads (VLs) and/or low CD4+ cell counts.

Method

This phase 3b, randomized (1:1), open-label, noninferiority study compared DTG/3TC versus BIC/FTC/TAF as first-line ART in adults with HIV-1. Participants were enrolled without baseline VL or CD4+ cell count restrictions and initiated treatment before availability of resistance testing results. The primary endpoint was the proportion of participants with HIV-1 RNA <50 copies/mL at week 48 (Snapshot; −10% noninferiority margin).

Results

Among 509 randomized participants (DTG/3TC, n = 254; BIC/FTC/TAF, n = 255), 47% had baseline VL ≥100 000 copies/mL and 16% had CD4+ cell count <200 cells/mm3. At week 48, DTG/3TC demonstrated noninferior efficacy to BIC/FTC/TAF, with HIV-1 RNA <50 copies/mL achieved in 89% and 92% of participants, respectively (adjusted difference, −3% [95% CI, −8%, 2%]). Median time to virologic suppression was rapid (4.1 weeks) in both groups. Confirmed virologic withdrawals were similar between groups (n = 7 each), with no treatment-emergent resistance identified. Safety outcomes were comparable.

Conclusions

Dolutegravir/Lamivudine demonstrated noninferior efficacy to BIC/FTC/TAF as initial ART, with no treatment-emergent resistance through week 48. These findings establish DTG/3TC as an effective and simplified initial ART regimen across a broad clinical spectrum. Clinical trial registration: ClinicalTrials.gov identification number, NCT05979311; URL, https://clinicaltrials.gov/study/NCT05979311

Schlagwörter

Stichwörter der Autor:innen

BIC/FTC/TAFDTG/3TCHIV-1antiretroviral therapytreatment naive

Autor:innen und Institutionen

  • INSERM UMR 1137 IAME, Université Paris Cité, Paris, France.
  • Service des Maladies Infectieuses, Assistance Publique - Hôpitaux de Paris Nord, Hôpital Bichat-Claude Bernard, Paris, France.
  • Imas12, UCM, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Fundacion Centro de Estudios Infectologicos, Buenos Aires, Argentina.
  • Department of Infectious Diseases and Hepatology, Nicolaus Copernicus University Ludwik Rydygier Collegium, Bydgoszcz, Poland.
  • Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.

ORCID-Profile: Jade Ghosn, Federico Pulido, Anita Olczak, Diego Ripamonti, Charlotte Martin, Maria Josefina Mendez Vazquez, Hiroyuki Gatanaga, Daniel Elbirt, Gary Whitlock, Richard Grove, Emilie Elliot, Bryn Jones, Piotr Budnik

Förderung

  • ViiV Healthcare

Zitieren

APA

Ghosn, J., Pulido, F., Lopardo, G. D., Olczak, A., Ripamonti, D., Martin, C., Paredes Ceballos, O., Stocker, H., Mendez Vazquez, M. J., Gatanaga, H., Metallidis, S., Elbirt, D., Whitlock, G., Mateo González, J. I., Mohammed, P., Wang, K., Grove, R., Wang, R., Jewell, A., …, & VOGUE Study Group (2026). VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment. Open Forum Infectious Diseases, 13(8). https://doi.org/10.1093/ofid/ofag471

Vancouver

Ghosn J, Pulido F, Lopardo GD, Olczak A, Ripamonti D, Martin C, et al. VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment. Open Forum Infectious Diseases. 2026;13(8). doi:10.1093/ofid/ofag471

BibTeX
@article{Ghosn2026,
  author = {Ghosn, Jade and Pulido, Federico and Lopardo, Gustavo D and Olczak, Anita and Ripamonti, Diego and Martin, Charlotte and Paredes Ceballos, Orlando and Stocker, Hartmut and Mendez Vazquez, Maria Josefina and Gatanaga, Hiroyuki and Metallidis, Simeon and Elbirt, Daniel and Whitlock, Gary and Mateo González, José Ignacio and Mohammed, Perry and Wang, Kehui and Grove, Richard and Wang, Ruolan and Jewell, Adelaide and Sutton, Kenneth and Elliot, Emilie and Moodley, Riya and Borsi, Rebecca and Jones, Bryn and Kisare, Michelle and Budnik, Piotr and van Wyk, Jean and VOGUE Study Group, VOGUE Study Group and VOGUE Study Group, VOGUE Study Group},
  title = {VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment},
  journal = {Open Forum Infectious Diseases},
  year = {2026},
  volume = {13},
  number = {8},
  doi = {10.1093/ofid/ofag471}
}
Kostenlos starten →